All In Biotech

BLA 019640 · Lilly

Humatrope

Somatropin · Injection

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Nov 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Oct 16, 1986

Approved uses

9

Original approval plus efficacy supplements

Registered trials

540

176 Phase 3, 31 recruiting

FAERS reports

11,846

6,001 serious, 475 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 20, 2026.

HUMATROPE is a recombinant human growth hormone indicated for: Pediatric Patients: growth failure due to inadequate secretion of endogenous growth hormone (GH); short stature associated with Turner syndrome; Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range; short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency; short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age. ( 1.1 ) Adult Patients: replacement of endogenous GH in adults with GH deficiency. ( 1.2 ) 1.1 Pediatric Patients HUMATROPE is indicated for the treatment of pediatric patients with: growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age. 1.2 Adult Patients HUMATROPE is indicated for the replacement of endogenous GH in adults with GH deficiency.

Mechanism: Somatropin binds to dimeric GH receptors located within the cell membranes of target tissue cells. This interaction results in intracellular signal transduction and subsequent induction of transcription and translation of GH-dependent proteins including IGF-1, IGF BP-3 and acid-labile subunit. Somatropin has direct tissue and metabolic effects or mediated indirectly by IGF-1, including stimulation of chondrocyte differentiation, and proliferation, stimulation of hepatic glucose output, protein synthesis and lipolysis. Somatropin stimulates skeletal growth in pediatric patients with GHD as a...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 12, 2009 Supplement 68 · Efficacy LabelLetter
  • Nov 1, 2006 Supplement 58 · Efficacy LetterLabel
  • Oct 12, 2005 Supplement 45 · Efficacy LabelLetter
  • Jul 25, 2003 Supplement 33 · Efficacy LetterLabelReview
  • Mar 11, 1997 Supplement 18 · Efficacy Review
  • Aug 1, 1996 Supplement 13 · Efficacy
  • Apr 15, 1994 Supplement 9 · Efficacy · priority review
  • May 10, 1989 Supplement 2 · Efficacy
  • Oct 16, 1986 Original approval · Type 5 - New Formulation or New Manufacturer · priority review
5 products under this application
  • HUMATROPE · SOMATROPIN 2MG/VIAL · INJECTABLE, INJECTION · Discontinued
  • HUMATROPE · SOMATROPIN 12MG/VIAL · INJECTABLE, INJECTION · Prescription
  • HUMATROPE · SOMATROPIN 5MG/VIAL · INJECTABLE, INJECTION · Prescription
  • HUMATROPE · SOMATROPIN 24MG/VIAL · INJECTABLE, INJECTION · Prescription
  • HUMATROPE · SOMATROPIN 6MG/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Somatropin" as an intervention, any sponsor and status, largest first.

All 540 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • incorrect dose administered1,016
  • injection site pain643
  • off label use511
  • headache481
  • drug dose omission431
  • fatigue424
  • underdose407
  • device leakage342
  • malaise325
  • wrong technique in product usage process260
  • drug ineffective244
  • drug dose omission by device222

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004148
2005161
2006156
2007212
2008197
2009350
2010277
2011327
2012388
2013197
2014272
20152,473
2016575
2017531
2018622
2019782
2020710
2021440
2022538
2023854
2024798
2025505
2026333

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Humatrope (Somatropin)

2024 spending

$6.1M

Beneficiaries

286

1,889 claims

Per beneficiary

$21,374

$1,462.35 per unit

View as table
YearSpending
2020$6,960,925
2021$6,457,216
2022$6,124,826
2023$6,210,736
2024$6,113,003

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 91 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.